|
1 kits (10 Vials)
| Yawan: | |
|---|---|
▎ Tsarin Retatrutid
Source: PubChem |
Jeri: YA⊃1;QGTFTSDYSI-L⊃2;LDKK⁴AQA⊃1;AFIEYLLEGGPSSGAPPPS⊃3; Tsarin kwayoyin halitta: C 221H 342N 46O68 Nauyin Kwayoyin: 4731 g/mol Lambar CAS: 2381089-83-2 PubChem CID: 171390338 Saukewa: LY3437943 |
▎ Binciken Retatrutid
Menene asalin bincike na Retatrutid?
Asalin bincike na Retatrutid yana da alaƙa da alaƙa da ƙara matsananciyar lamuran duniya na kiba da ciwon sukari, da kuma iyakancewar magungunan warkewa da ake da su: kiba da ciwon sukari suna haifar da babbar barazana ga lafiyar jama'a, tare da yawan kiba na duniya zai kai biliyan 4.005 nan da 2035 kuma adadin masu ciwon sukari ya karu zuwa miliyan 592, wanda ya haifar da babbar illa ga lafiyar duniya. Multi-manufa agonist agonist peptides sun fito ne a matsayin mafita, mai iya hana kiba, magance ciwon sukari, da kuma guje wa illa masu guba na magungunan da ake da su, yana mai da su yanayin haɓakar kiba da maganin ciwon sukari.
Menene tsarin aikin Retatrutid?
Daidaita metabolism na makamashi ta hanyar kunnawa da yawa masu karɓa
Retatrutid agonist mai karɓa sau uku ne wanda ke yin niyya ga mai karɓar mai karɓar insulinotropic polypeptide mai dogaro da glucose (GIPR), mai karɓar glucagon-like peptide-1 (GLP-1R), da mai karɓar glucagon (GCGR). A lokaci guda yana kunna waɗannan masu karɓa guda uku, yana daidaita ƙarfin kuzari ta hanyoyi da yawa.
Ayyukan GIPR agonist:
GIP shine hormone mai ɓoye insulin na hanji wanda ƙwayoyin K hanji ke ɓoye kuma ana fitar dasu bayan abinci. Retatrutid yana kunna GIPR, yana haɓaka haɓakar insulin, haɓaka haɓakar insulin, kuma ta haka yana taimaka wa jiki sosai don sha da amfani da glucose, ta haka yana rage matakan glucose na jini. Bugu da ƙari, GIP na iya rinjayar metabolism mai mai ta hanyar daidaita aikin adipocyte da rage yawan kitse [1].
Ayyukan agonist na GLP-1R:
GLP-1 shine hormone peptide wanda aka ɓoye ta ƙwayoyin L na hanji. Bayan kunna GLP-1R, Retatrutid yana haifar da fa'idodi daban-daban. Yana ba da gudummawa ga samar da insulin a cikin yanayin da ya dogara da matakin glucose, don haka rage matakan sukari a cikin jini. Yana iya jinkirta zubar da ciki, ƙara koshi, da rage cin abinci. GLP-1R tashin hankali na iya aiki akan tsarin juyayi na tsakiya, yana daidaita ci da ma'aunin kuzari, ta haka yana taimakawa rage nauyi [2].
GCGR agonists:
Glucagon yawanci yana ƙara matakan glucose na jini, amma ƙarƙashin tasirin Retatrutid, ƙwannafi na GCGR yana haifar da tasiri daban-daban. Yana inganta glycogenolysis da gluconeogenesis a cikin hanta. A ƙarƙashin tasirin haɗin gwiwar Retatrutid, jiki ba ya samun sauƙi mai sauƙi a cikin matakan glucose na jini amma a maimakon haka yana daidaita makamashin makamashi don ƙara raguwar mai, ta haka yana samun asarar nauyi da inganta haɓaka. GCGR agonist na iya rinjayar hanta lipid metabolism, rage yawan kitsen hanta [3].
Tasiri kan Tsarukan Jiki Masu Dangantaka da Metabolism
Ta hanyar aiki lokaci guda akan masu karɓa guda uku da aka ambata, Retatrutid yana rinjayar matakai masu alaƙa da metabolism da yawa.
Tsarin glucose na jini:
Ta hanyar kunna GIPR da GLP-1R don haɓaka ƙwayar insulin, da kuma daidaita GCGR daidai, Retatrutid na iya rage matakan glucose na jini. Sakamakonsa na hypoglycemic yana bayyana lokacin da glucose na jini ya tashi, yayin da ba zai iya haifar da hypoglycemia ba yayin da glucose na jini ya zama al'ada, wanda ke da amfani ga sarrafa glucose na jini a cikin masu ciwon sukari [4]..
Gudanar da nauyi:
Retatrutid yana nuna tasiri mai mahimmanci a cikin sarrafa nauyi. Ta hanyar kunna GLP-1R, yana rage jinkirin zubar da ciki, yana ƙara jin daɗi, kuma yana rage cin abinci; ta hanyar daidaita metabolism na mai, yana inganta rushewar kitse da kashe kuzari, ta yadda ake samun asarar nauyi. Gwajin asibiti sun nuna cewa marasa lafiya masu kiba ko masu kiba da aka bi da su tare da Retatrutid sun sami babban asarar nauyi a kan wani ɗan lokaci [5,6].
Tsarin lipid:
Maganin Retatrutid yana inganta bayanan lipid na marasa lafiya. Yana rage triglyceride (TG), low-density lipoprotein cholesterol (LDL-C), da kuma low-density lipoprotein cholesterol matakan (VLDL-C), yayin da kuma daidaita apolipoproteins, kamar runtse apolipoprotein B (apoB) da apolipoprotein C -III (apoprotein da ke da alaƙa da atherosclerosis, rage adadin lipoprotein da lipoproteins). inganta lafiyar zuciya [7].
Inganta hanta lipid metabolism:
Ga marasa lafiya da cututtukan hanta maras-giya (NAFLD) da ke da alaƙa da tabarbarewar rayuwa, Retatrutid yana rage yawan kitsen hanta. A cikin gwaje-gwajen da suka dace na asibiti, marasa lafiya da aka bi da su tare da allurai daban-daban na Retatrutid sun nuna raguwar dangi mai yawa a cikin abun ciki na hanta idan aka kwatanta da tushe, yana nuna cewa Retatrutid yana da tasiri mai kyau akan tsarin hanta mai metabolism, wanda ke da fa'ida don inganta aikin hanta [3]..
Hoto 1 Hanyoyin aikin Retatrutid [8].
Menene aikace-aikacen Retatrutid?
Maganin Kiba:
Kiba ya zama babban batun kiwon lafiyar jama'a a duniya, wanda ke da alaƙa da farawa da ci gaban cututtuka daban-daban. Retatrutid ya nuna tasiri mai mahimmanci a cikin maganin kiba. Marasa lafiya masu kiba da aka yi musu magani tare da Retatrutid sun sami gagarumin raguwar nauyin jiki. A cikin nazarin kiba na mako 48 na Phase 2, marasa lafiya da aka bi da su tare da 8mg da 12mg na Retatrutid sun sami raguwar nauyi na 22.8% da 24.2%, bi da bi. A wani mataki na 2 makafi sau biyu, bazuwar, gwajin sarrafa wuribo, marasa lafiya a cikin ƙungiyoyin kashi daban-daban sun sami nau'ikan asarar nauyi a makonni 24 da makonni 48. Ƙungiyar 12mg ta sami asarar nauyi na 24.2% a makonni 48, yayin da ƙungiyar placebo kawai ta ga raguwar -2.1%. Retatrutid yadda ya kamata yana rage nauyin jiki a cikin marasa lafiya masu kiba, yana ba da sabon kayan aiki mai ƙarfi don maganin kiba. Maganin Retatrutid don kiba ba kawai yana rage nauyin jiki ba amma yana iya inganta wasu al'amurran kiwon lafiya da ke da alaka da kiba, irin su kawar da matsalolin haɗin gwiwa da kuma kawar da alamun cututtuka na haɗin gwiwa da ke da alaka da kiba ta hanyar asarar nauyi; Rage kiba na iya taimakawa inganta matsalolin da ke da alaƙa da kiba kamar su bacci [3,6].
Nau'in ciwon sukari na 2:
Nau'in ciwon sukari na 2 cuta ce ta rayuwa ta yau da kullun wacce ke da juriya na insulin da rashin isasshen ƙwayar insulin. Retatrutid yana da yuwuwar ƙimar aikace-aikacen a cikin kula da nau'in ciwon sukari na 2. Yana motsa siginar insulin ta hanyar kunna mai karɓar GLP-1, yana inganta juriya na insulin, yana rage matakan glucose na jini. Har ila yau, tasirinsa na rage nauyi yana taimakawa wajen inganta yanayin marasa lafiya na nau'in ciwon sukari na 2, saboda kiba yana da mahimmancin haɗari ga nau'in ciwon sukari na 2, kuma asarar nauyi na iya haɓaka haɓakar insulin, yana ƙara taimakawa wajen sarrafa glucose na jini. A cikin binciken da ya shafi marasa lafiya da nau'in ciwon sukari na 2, Retatrutid ya haifar da asarar nauyi mai yawa da kuma raguwa mai mahimmanci a matakan haemoglobin A1c (HbA1c), tare da HbA1c yana raguwa da 1.64% idan aka kwatanta da placebo. Wannan yana nuna cewa Retatrutid ba wai kawai yana sarrafa matakan glucose na jini yadda ya kamata ba amma yana inganta yanayin gabaɗayan marasa lafiya da ke da nau'in ciwon sukari na 2 ta hanyoyi da yawa, gami da asarar nauyi, ta haka ne ke haɓaka ingancin rayuwarsu [6]..
Maganin ciwon hanta mara-giya (NAFLD):
NAFLD wani rauni ne na hanta da ke haifar da danniya wanda ke da alaƙa da juriya na insulin da raunin kwayoyin halitta, wanda ya ƙunshi nau'ikan yanayi ciki har da hanta mai sauƙi mara-giya, steatohepatitis mara giya, da cirrhosis masu alaƙa. Retatrutid yana nuna yuwuwar yuwuwar a cikin jiyya na NAFLD. A cikin bazuwar, makafi biyu, gwajin sarrafa placebo wanda ya haɗa da mahalarta tare da cututtukan hanta da ke da alaƙa da cututtukan hanta da cututtukan hanta da abun ciki na hanta ≥10%, a cikin makonni 24, ma'anar canjin dangi a cikin abun ciki mai hanta daga tushe ya bambanta sosai a cikin rukunin kashi na Retatrutid: -81.4% a cikin rukunin 8mg, -82.4% a cikin rukunin + 12.4%, da +10.bo. Wannan yana nuna cewa Retatrutid na iya rage yawan kitsen hanta yadda ya kamata, wanda ke da mahimmancin mahimmanci don haɓaka cututtukan hanta na marasa lafiya na NAFLD. Yana ɗaukar alkawari azaman sabon zaɓi na magani don NAFLD, mai yuwuwar rage jinkirin ci gaban cuta da rage haɗarin rikice-rikice kamar cirrhosis [3].
Kammalawa
Retatrutid yana nuna yuwuwar yuwuwar haɓaka yanayin cututtukan hanta na marasa lafiya na NAFLD, yin aiki ta hanyoyi da yawa ciki har da daidaita ƙarfin kuzari, haɓaka juriya na insulin, tasirin anti-mai kumburi, da daidaita metabolism na lipid.
Game da Marubuci
Abubuwan da aka ambata a sama duk bincike ne, gyara su kuma Cocer Peptides ne suka haɗa su.
Mawallafin Jaridar Kimiyya
Rosenstock, J fitaccen malami ne wanda aikinsa ke da alaƙa da alaƙa da manyan cibiyoyi da yawa, gami da Jami'ar Texas Southwestern Medical Center, Jami'ar Texas Dallas, da Cibiyar VIGOR ta Kanada. Bincikensa ya mamaye fannoni da yawa irin su Endocrinology & Metabolism, General & Internal Medicine, Tsarin zuciya da jijiyoyin jini, Magungunan Magunguna & Magunguna, da Bincike & Magungunan Gwaji. Gudunmawar da ya bayar ga al'ummar ilimi ta sami karbuwa sosai, kamar yadda aka tabbatar ta hanyar zaɓen da aka maimaita a matsayin 'Mai bincike mai zurfi a fagen ilimin likitanci' daga 2017 zuwa 2024, yana nuna muhimmiyar matsayinsa da babban tasiri a binciken likitancin asibiti. An jera Rosenstock J a cikin ambaton ambaton [4].
